Response to ABVD chemotherapeutic protocol in patients with early stage Hodgkin's lymphoma

Simple item page
dc.contributor.authorDiaz, Javier
dc.contributor.authorSoto, Katherine
dc.contributor.authorErnst, Daniel
dc.date.accessioned2024-01-10T13:17:15Z
dc.date.available2024-01-10T13:17:15Z
dc.date.issued2017
dc.description.abstractBackground: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. Aim: To report the experience in the treatment of ESHL. Material and Methods: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015. Results: Twenty-two patients were treated. In 73%, the tumor was of nodular sclerosis histologic type. Most patients (95%) were in stage II, and 78% had a favorable prognosis according to the Deutsche Hodgkin Studiengruppe (GHSG) criteria. All patients were stratified using PET-CT and treated using the ABVD CT protocol, for 4-6 cycles. Only 5 patients received RT. There was no change of conduct after interim-PET-CT results. Ninety one percent of patients achieved complete response and there were two cases of refractory disease. Both cases underwent hematopoietic stem cell transplantation. After 17 months of median follow-up, 91% of patients are relapse-free, and only one patient died (5%). Conclusions: ABVD offers excellent results for ESHL patients. The benefit of PET-CT should be evaluated with prospective protocols, aiming to select patients needing RT or to reduce the number of CT cycles.
dc.format.extent4 páginas
dc.fuente.origenWOS
dc.identifier.eissn0717-6163
dc.identifier.issn0034-9887
dc.identifier.pubmedidMEDLINE:28898338
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78649
dc.identifier.wosidWOS:000404912900009
dc.information.autorucMedicina;Diaz J;S/I;238008
dc.information.autorucMedicina;Ernst D;S/I;132753
dc.information.autorucMedicina;Soto K;S/I;155432
dc.issue.numero5
dc.language.isoes
dc.nota.accesoSin adjunto
dc.pagina.final622
dc.pagina.inicio619
dc.publisherSOC MEDICA SANTIAGO
dc.revistaREVISTA MEDICA DE CHILE
dc.rightsregistro bibliográfico
dc.subjectChile
dc.subjectHodgkin Disease
dc.subjectLymphoma
dc.subjectPositron Emission Tomography Computed Tomography
dc.subjectTRIAL
dc.subjectGUIDELINES
dc.subjectTHERAPY
dc.subjectCANCER
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleResponse to ABVD chemotherapeutic protocol in patients with early stage Hodgkin's lymphoma
dc.typeartículo
dc.volumen145
sipa.codpersvinculados238008
sipa.codpersvinculados132753
sipa.codpersvinculados155432
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Collections
Artículos de revistas